Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies

10.1177/1747493016676615International Journal of Stroke123285-29

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial

10.1016/j.trci.2018.12.001Alzheimer's and Dementia: Translational Research and Clinical Interventions538-4

Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset

10.1159/000525984Cerebrovascular Disease

Concomitant coronary artery disease among Asian ischaemic stroke patients

Annals of the Academy of Medicine Singapore377573-575AAMS

Limb-shaking transient ischemic attack with distal micro-embolic signals and impaired cerebrovascular reactivity using transcranial doppler

Annals of the Academy of Medicine Singapore377619-620AAMS

B vitamins and cognition in subjects with small vessel disease: A Substudy of VITATOPS, a randomized, placebo-controlled trial

10.1016/j.jns.2017.05.061Journal of the Neurological Sciences379124-12

Vascular cognitive impairment

The term vascular cognitive impairment (VCI) was introduced around the start of the new millennium and refers to the contribution of vascular pathology to any severity of cognitive impairment, ranging from subjective cognitive decline and mild cognitive impairment to dementia. Although vascular pathology is common in elderly individuals with cognitive decline, pure vascular dementia (that is, dementia caused solely by vascular pathology) is uncommon. Indeed, most patients with vascular dementia also have other types of pathology, the most common of which is Alzheimer disease (specifically, the diffuse accumulation of amyloid-\u3b2 plaques and neurofibrillary tangles composed of tau). At present, the main treatment for VCI is prevention by treating vascular diseases and other risk factors for VCI, such as hypertension and diabetes mellitus. Despite the current paucity of disease-modifying pharmacological treatments, we foresee that eventually, we might be able to target specific brain diseases to prevent cognitive decline and dementia

Subtyping of circulating exosome-bound amyloid ? reflects brain plaque deposition

10.1038/s41467-019-09030-2Nature Communications101114

CHIMES-I: Sub-group analyzes of the effects of NeuroAiD according to baseline brain imaging characteristics among patients randomized in the CHIMES study

10.1111/ijs.12044International Journal of Stroke86491-49